{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:06:08Z","timestamp":1782489968367,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014039","name":"DOD Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["C33589\/A28284"],"award-info":[{"award-number":["C33589\/A28284"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016916","name":"Royal Marsden Cancer Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ctro.2025.100985","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T12:33:58Z","timestamp":1748954038000},"page":"100985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ultrahypofractionated radiotherapy for localised prostate cancer: The impact of daily MRI-guided adaptive radiotherapy on delivered dose"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-5174","authenticated-orcid":false,"given":"S.E.","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-3349","authenticated-orcid":false,"given":"R.A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7542-0622","authenticated-orcid":false,"given":"T.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-3806","authenticated-orcid":false,"given":"J.","family":"Nartey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Oelfke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"McNair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2025.100985_b0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2019.08.027","article-title":"ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer","volume":"141","author":"Ghadjar","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijrobp.2011.11.047","article-title":"Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer","volume":"84","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2025.100985_b0015","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2018.07.2006","article-title":"Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial","volume":"102","author":"de Crevoisier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2025.100985_b0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2019.10.017","article-title":"A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer","volume":"142","author":"Murray","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.radonc.2013.04.007","article-title":"Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy","volume":"107","author":"Kok","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-016-0681-z","article-title":"Dosimetric impact of different bladder and rectum filling during prostate cancer radiotherapy","volume":"11","author":"Chen","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3857\/roj.2018.00514","article-title":"Interfraction variation and dosimetric changes during image-guided radiation therapy in prostate cancer patients","volume":"37","author":"Fuchs","year":"2019","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.ctro.2025.100985_b0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/0284186X.2022.2062682","article-title":"Radiation-induced prostate swelling during SBRT of the prostate","volume":"61","author":"Vanhanen","year":"2022","journal-title":"Acta Oncol (madr)"},{"key":"10.1016\/j.ctro.2025.100985_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-9-22","article-title":"Change in prostate volume during extreme hypo-fractionation analysed with MRI","volume":"9","author":"Gunnlaugsson","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0050","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/j.clon.2022.03.022","article-title":"Prostate volume changes during extreme and moderately Hypofractionated magnetic resonance image-guided radiotherapy","volume":"34","author":"Alexander","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0055","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.radonc.2021.12.037","article-title":"Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: a post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy","volume":"167","author":"Ma","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0060","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.prro.2020.07.003","article-title":"Time analysis of online Adaptive magnetic resonance\u2013guided radiation therapy workflow according to anatomical sites","volume":"11","author":"G\u00fcng\u00f6r","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0065","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/1754-9485.13336","article-title":"Early experience with MR-guided adaptive radiotherapy using a 1.5 T MR-Linac: first 6 months of operation using adapt to shape workflow","volume":"66","author":"de Leon","year":"2022","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0070","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-021-01872-9","article-title":"Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy","volume":"16","author":"Eckl","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-021-01916-0","article-title":"Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer","volume":"16","author":"Schaule","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0080","first-page":"1","author":"Van As","year":"2020","journal-title":"Pace Trials A C"},{"key":"10.1016\/j.ctro.2025.100985_b0085","unstructured":"Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment (PERMIT) n.d. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03727698 (accessed June 14, 2024)."},{"key":"10.1016\/j.ctro.2025.100985_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01328","article-title":"The MOMENTUM study: an international registry for the evidence-based introduction of MR-guided Adaptive therapy","volume":"10","author":"de Mol van Otterloo","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.616291","article-title":"MR-guided radiotherapy for prostate cancer","volume":"10","author":"Tocco","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0100","first-page":"54","article-title":"Adaptive radiotherapy: the Elekta Unity MR-linac concept","volume":"18","author":"Winkel","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0105","first-page":"35","article-title":"Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: initial clinical experiences and assessment of delivered doses compared to a C-arm linac","volume":"23","author":"Dunlop","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109457","article-title":"Evaluation of therapeutic radiographer contouring for magnetic resonance image guided online adaptive prostate radiotherapy","volume":"180","author":"Adair Smith","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.1086258","article-title":"Dose accumulation for MR-guided adaptive radiotherapy: from practical considerations to state-of-the-art clinical implementation","volume":"12","author":"McDonald","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0120","unstructured":"Mukaka MM. Statistics Corner: A guide to appropriate use of Correlation coefficient in medical research. vol. 24. 2012."},{"key":"10.1016\/j.ctro.2025.100985_b0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tipsro.2022.08.005","article-title":"Impact of intrafraction changes in delivered dose of the day for prostate cancer patients treated with stereotactic body radiotherapy via MR-linac","volume":"23","author":"Dang","year":"2022","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2025.100985_b0135","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-Year outcomes from PACE B: an international phase III randomized controlled trial Comparing stereotactic body radiotherapy (SBRT) vs. conventionally Fractionated or moderately hypo Fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.ctro.2025.100985_b0140","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05709496. Dose De-escalation in Prostate Radiotherapy Using the MRL (DESTINATION) 2024."},{"key":"10.1016\/j.ctro.2025.100985_b0145","doi-asserted-by":"crossref","unstructured":"Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. ANALYSIS OF INTRAPROSTATIC FAILURES IN PATIENTS TREATED WITH HORMONAL THERAPY AND RADIOTHERAPY: IMPLICATIONS FOR CONFORMAL THERAPY PLANNING. 2002.","DOI":"10.1016\/S0360-3016(02)02795-5"},{"key":"10.1016\/j.ctro.2025.100985_b0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijrobp.2019.12.044","article-title":"Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: a toxicity and quality-of-life Comparison of two prospective trials","volume":"107","author":"Alayed","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2025.100985_b0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109441","article-title":"SBRT focal dose intensification using an MR-linac adaptive planning for intermediate-risk prostate cancer: an analysis of the dosimetric impact of intra-fractional organ changes","volume":"179","author":"Brennan","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0165","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3390\/cancers16112073","article-title":"Stereotactic body radiotherapy (SBRT) to localised prostate cancer in the era of MRI-guided Adaptive radiotherapy: doses delivered in the HERMES trial Comparing two-and five-Fraction treatments","volume":"16","author":"Westley","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2025.100985_b0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose\u2013effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0175","doi-asserted-by":"crossref","unstructured":"Martin JM, Richardson M, Siva S, Cardoso M, Handmer M, Sidhom M. Review Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. 2022.","DOI":"10.1016\/S1470-2045(22)00544-7"},{"key":"10.1016\/j.ctro.2025.100985_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-9-174","article-title":"Seminal vesicle intrafraction motion analysed with cinematic magnetic resonance imaging","volume":"9","author":"Gill","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2022.02.002","article-title":"Seminal vesicle inter- and intra-fraction motion during radiotherapy for prostate cancer: a review","volume":"169","author":"Brand","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0190","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.radonc.2021.07.014","article-title":"Seminal vesicle intrafraction motion during the delivery of radiotherapy sessions on a 1.5 T MR-linac","volume":"162","author":"de Muinck Keizer","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0195","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.meddos.2011.09.002","article-title":"Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer","volume":"37","author":"Stenmark","year":"2012","journal-title":"Med Dosim"},{"key":"10.1016\/j.ctro.2025.100985_b0200","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.radonc.2008.03.016","article-title":"Dosimetric evaluation of prostate rotations and their correction by couch rotations","volume":"88","author":"van Herten","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0205","article-title":"GI factors, potential to predict prostate motion during radiotherapy; a scoping review","volume":"40","author":"Alexander","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2020.06.044","article-title":"Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-linac","volume":"151","author":"de Muinck Keizer","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0215","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.prro.2014.06.005","article-title":"A systematic review: effectiveness of rectal emptying preparation in prostate cancer patients","volume":"4","author":"McNair","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0220","article-title":"Imageguided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction","volume":"87","author":"Maund","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctro.2025.100985_b0225","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2010.12.005","article-title":"A significant decrease in rectal volume and diameter during prostate IMRT","volume":"98","author":"Anderson","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0230","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-020-01681-6","article-title":"Strict bladder filling and rectal emptying during prostate SBRT: does it make a dosimetric or clinical difference?","volume":"15","author":"Byun","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2012.11324.x","article-title":"An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011","volume":"111","author":"Eifler","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.ctro.2025.100985_b0245","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.3390\/curroncol30070483","article-title":"Seminal vesicle treatment for localized prostate cancer treated with external beam radiotherapy","volume":"30","author":"Steed","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0250","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.juro.2008.08.037","article-title":"The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from southwest oncology group 8794","volume":"180","author":"Swanson","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2025.100985_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2024.1379596","article-title":"Magnetic resonance image-guided adaptive radiotherapy enables safe CTV-to-PTV margin reduction in prostate cancer: a cine MRI motion study","volume":"14","author":"Westley","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2025.100985_b0260","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210001","article-title":"Clinical use, challenges, and barriers to implementation of deformable image registration in radiotherapy \u2013 the need for guidance and QA tools","volume":"94","author":"Hussein","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctro.2025.100985_b0265","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ad0d8a","article-title":"Review and recommendations on deformable image registration uncertainties for radiotherapy applications","volume":"68","author":"Nenoff","year":"2023","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ctro.2025.100985_b0270","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semradonc.2023.10.003","article-title":"The use of MR-guided radiation therapy for head and neck cancer and recommended reporting guidance","volume":"34","author":"McDonald","year":"2024","journal-title":"Semin Radiat Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:33:44Z","timestamp":1762623224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630825000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":54,"alternative-id":["S2405630825000771"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2025.100985","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultrahypofractionated radiotherapy for localised prostate cancer: The impact of daily MRI-guided adaptive radiotherapy on delivered dose","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2025.100985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100985"}}